Amandine Gouverneur

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer

Julien Bezin, Amandine Gouverneur, Marine Pénichon et al. · Diabetes Care · 2022 · 293 citations

Medicine, Endocrinology, Oncology +15

A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events

Jean‐Luc Faillie, Pili Ferrer, Amandine Gouverneur et al. · Journal of Clinical Epidemiology · 2017 · 51 citations · Full text

Pharmacy, Pharmacology, Clinical Pharmacology +16

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer

Pietro Rosellini, Samuel Amintas, Charline Caumont et al. · European Journal of Cancer · 2022 · 45 citations

Medicine, Molecular Genetics, Oncology +11

JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study

Amandine Gouverneur, Jérôme Avouac, Clément Prati et al. · European Journal of Clinical Pharmacology · 2022 · 34 citations

Medicine, Hematology, Pharmacology +14

Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study

Samy Babai, Anne-Laure Voisin, Célia Bertin et al. · Drug Safety · 2019 · 32 citations

Life Sciences, Immunology, Oncology +16